[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349835-105":59,"doc-detail-349835-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identification-of-a-myosin-1b-binding-aptamer-for-fluorescence-imaging-and-targeted-therapy-of-esophageal-squamous-cell-carcinoma","Identification of a myosin 1B-binding aptamer for fluorescence imaging and targeted therapy of esophageal squamous cell carcinoma","","Esophageal squamous cell carcinoma (ESCC) remains a major global health challenge, with limited diagnostic sensitivity and insufficient therapeutic targeting leading to advanced-stage presentation and poor survival. Using Cell-SELEX, high-affinity aptamers against KYSE30 cells were screened, showing selective binding across multiple cancer types. A sequence-optimized truncated aptamer, Z4-6, preserved binding while supporting Cy5-labeled fluorescent probes that recognize ESCC tissues with minimal staining of adjacent non-cancerous tissue. Myosin 1B was identified as the Z4-6 molecular target via pull-down and RNA interference. Z4-6 was further used to load doxorubicin in Z4-6-Dox conjugates, producing selective cytotoxicity in vitro and effective tumor growth inhibition in vivo with reduced cardiotoxicity, supporting potential for precise detection and targeted therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-a-myosin-1b-binding-aptamer-for-fluorescence-imaging-and-targeted-therapy-of-esophageal-squamous-cell-carcinoma/349835/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-a-myosin-1b-binding-aptamer-for-fluorescence-imaging-and-targeted-therapy-of-esophageal-squamous-cell-carcinoma/349835.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the clinical problem addressed in the study?","Question",{"text":112,"@type":113},"The study targets the inadequate diagnosis and non-specific treatment of esophageal squamous cell carcinoma (ESCC), which contributes to late detection, recurrence, and poor prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the ESCC-binding aptamers identified?",{"text":117,"@type":113},"Aptamers with high affinity for KYSE30 cells were screened using Cell-based Systematic Evolution of Ligands by EXponential enrichment (Cell-SELEX).",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular target and therapeutic approach were developed from the aptamer?",{"text":121,"@type":113},"Myosin 1B was identified as the molecular target of the aptamer Z4-6. Z4-6 was used to construct Z4-6-Dox conjugates by noncovalent loading with doxorubicin for targeted ESCC therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349835,1790397399,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Materials Today Bio 37 (2026) 102867  \nContents lists available at ScienceDirect  \nMaterials Today Bio  \njournal [homepage:](homepage: www.journals.elsevier.com/materials-today-bio)[ www.journals.elsevier.com/materials-today-bio](homepage: www.journals.elsevier.com/materials-today-bio)  \nIdentification of a myosin 1B-binding aptamer for fluorescence imaging and targeted therapy of esophageal squamous cell carcinoma  \nZhaoting Wang a,1, Xiaoxiong Xiao b,c,1, Tianlu Zhang a,1, Xiao Lia, Mengmeng Jia,  \nYongqi Qiana, Xue Baia, Xin Lia,d, Jing Lua,d, Jinlu Tang a, Kangdong Liu a,d,e, Zhaohui Lif,*, Baoyin Yuan a,d,**   \na School of Basic Medical Sciences, State Key Laboratory of Metabolic Dysregulation & the Prevention and Treatment of Esophageal Cancer, Zhengzhou University, Zhengzhou, Henan, 450001, China  \nb Department of Thoracic Surgery, Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan, 410083, China c National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, 410008, China  \nd Henan Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou, Henan, 450000, China e China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, 450003, China  \nf College of Chemistry, Henan Joint International Research Laboratory of Green Construction of Functional Molecules and Their Bioanalytical Applications, Zhengzhou University, Zhengzhou, Henan, 450001, China  \n\n| A B S T R A C T |\n| --- |\n| Esophageal squamous cell carcinoma (ESCC), a prevalent subtype of esophageal cancer, poses a significant global health challenge. The current diagnostic and therapeutic approaches for ESCC are inadequate, highlighting the urgent need for the development of novel recognition molecules and the identification of new therapeutic targets to facilitate early diagnosis and targeted therapy. In this work, several aptamers with high affinity to target KYSE30 cells are screened through Cell-based Systematic Evolution of Ligands by EXponential enrichment (Cell-SELEX). These aptamers show distinct binding to multiple cancer cells including ESCC, gastric cancer and liver cancer cells. Meanwhile, a truncated aptamer Z4-6 that retains comparable binding affinity is achieved via sequence optimization. With Z2 and Z4-6 aptamers as the recognition elements, Cy5-labeled fluorescent aptamer probes have demonstrated the ability to specifically recognize ESCC tissues while sparing adjacent non-cancerous tissues, suggesting their potential utility as detection probes in the clinical diagnosis of ESCC. Furthermore, myosin 1B has been identified as the molecular target of the aptamer Z4-6 through pull-down and RNA interference assays, underscoring its promise as a tumor biomarker and therapeutic target. The Z4-6 aptamer has been employed to construct Z4-6-Dox conjugates via noncovalent loading with doxorubicin (Dox) for the targeted therapy of ESCC. In vitro cytotoxicity assays have revealed that Z4-6-Dox selectively induces cytotoxicity in KYSE30 cells. Notably, the Z4-6 aptamer demonstrates in vivo tumor-targeting capabilities, and Z4-6-Dox effectively inhibits tumor cell growth with reduced cardiotoxicity. This study contributes valuable molecular recognition tools and identifies a potential target for the precise diagnosis and targeted therapy of ESCC. |\n\n1. Introduction  \nEsophageal cancer is a prevalent malignant tumor that poses a significant threat to human health, ranking seventh in mortality and eleventh in incidence globally [1]. This cancer primarily consists of two subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) [2]. Notably, over 70% of esophageal cancer cases are reported in China, with ESCC making up about 90% of these diagnoses [3]. The early symptoms of ESCC are often subtle, leading to a majority of patients being diagnosed at an advanced stage with  \nmetastasis, which contributes to a high recurrence rate and poor prognosis. The five-year overal","cbCaisCjMWJkNGFK","https://ap.wps.com/l/cbCaisCjMWJkNGFK","pdf",13079444,14,"English","# Abstract\n# Introduction","[{\"question\":\"What is the clinical problem addressed in the study?\",\"answer\":\"The study targets the inadequate diagnosis and non-specific treatment of esophageal squamous cell carcinoma (ESCC), which contributes to late detection, recurrence, and poor prognosis.\"},{\"question\":\"How were the ESCC-binding aptamers identified?\",\"answer\":\"Aptamers with high affinity for KYSE30 cells were screened using Cell-based Systematic Evolution of Ligands by EXponential enrichment (Cell-SELEX).\"},{\"question\":\"What molecular target and therapeutic approach were developed from the aptamer?\",\"answer\":\"Myosin 1B was identified as the molecular target of the aptamer Z4-6. Z4-6 was used to construct Z4-6-Dox conjugates by noncovalent loading with doxorubicin for targeted ESCC therapy.\"}]","Identification of a myosin 1B-binding aptamer for fluorescence imaging and targeted therapy of esophageal squamous cell carcinoma | PDF",1790085886,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaabbc2540663fe9dbd0bc8b3a1e15c4.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cec1e30a99d76f5aefc923a85606ee22.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0a0608d345a5bba09cf91f34a49497f.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/224c5f45db57b1716efdad6b1f7fb6af.webp",980,1306]